(Q37798193)

23 August 2017

title

Advances in the evaluation and management of minimal hepatic encephalopathy (English)

1 reference

23 August 2017

2

Jasmohan S Bajaj

1 reference

23 August 2017

author name string

Jennifer Y Montgomery

series ordinal

1

1 reference

23 August 2017

publication date

1 February 2011

1 reference

Current gastroenterology reports

23 August 2017

published in

1 reference

23 August 2017

volume

13

1 reference

23 August 2017

issue

1

1 reference

23 August 2017

page(s)

26-33

1 reference

https://scigraph.springernature.com/pub.10.1007/s11894-010-0150-z

23 August 2017

exact match

0 references

cites work

Spectrum of neurocognitive impairment in cirrhosis: Implications for the assessment of hepatic encephalopathy

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0150-Z

Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0150-Z

Review of the final report of the 1998 Working Party on definition, nomenclature and diagnosis of hepatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0150-Z

Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0150-Z

Minimal hepatic encephalopathy: consensus statement of a working party of the Indian National Association for Study of the Liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0150-Z

Minimal hepatic encephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0150-Z

Predictors of minimal hepatic encephalopathy in patients with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0150-Z

Minimal hepatic encephalopathy matters in daily life

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0150-Z

Natural history of minimal hepatic encephalopathy in patients with extrahepatic portal vein obstruction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0150-Z

Screening of subclinical hepatic encephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0150-Z

Impairment of driving ability and neuropsychological function in patients with MHE disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0150-Z

Minimal hepatic encephalopathy impairs fitness to drive.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0150-Z

The effect of fatigue on driving skills in patients with hepatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0150-Z

Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0150-Z

Hepatic encephalopathy and fitness to drive.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0150-Z

Changing face of hepatic encephalopathy: role of inflammation and oxidative stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0150-Z

Oxidative stress markers in the brain of patients with cirrhosis and hepatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0150-Z

Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0150-Z

The pathophysiologic basis of hepatic encephalopathy: central role for ammonia and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0150-Z

Role of ammonia and inflammation in minimal hepatic encephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0150-Z

Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0150-Z

Inhibitory control test for the diagnosis of minimal hepatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0150-Z

Development of a three-factor neuropsychological approach for detecting minimal hepatic encephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0150-Z

Detection of minimal hepatic encephalopathy: normalization and optimization of the Psychometric Hepatic Encephalopathy Score. A neuropsychological and quantified EEG study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0150-Z

Critical flicker frequency for quantification of low-grade hepatic encephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0150-Z

Improving the inhibitory control task to detect minimal hepatic encephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0150-Z

Motor impairment in liver cirrhosis without and with minimal hepatic encephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0150-Z

Two-dimensional MR spectroscopy of minimal hepatic encephalopathy and neuropsychological correlates in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0150-Z

Minimal hepatic encephalopathy: diagnosis, clinical significance and recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0150-Z

Three targets of branched-chain amino acid supplementation in the treatment of liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0150-Z

A double-blind, randomized, placebo-controlled trial of intravenous L-ornithine-L-aspartate on postural control in patients with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0150-Z

Probiotic yogurt for the treatment of minimal hepatic encephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0150-Z

Rifaximin treatment in hepatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0150-Z

Review article: the modern management of hepatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0150-Z

Pharmacology and safety of glycerol phenylbutyrate in healthy adults and adults with cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0150-Z

Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0150-Z

Diagnosis and Prognostic Significance of Minimal Hepatic Encephalopathy in Patients with Cirrhosis of Liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0150-Z

Variations in the promoter region of the glutaminase gene and the development of hepatic encephalopathy in patients with cirrhosis: a cohort study

21 January 2018

1 reference

12 December 2020

Minimal hepatic encephalopathy.

1 reference

12 December 2020

Subclinical hepatic encephalopathy impairs daily functioning

1 reference

12 December 2020

The prognostic significance of subclinical hepatic encephalopathy

1 reference

12 December 2020

Minimal hepatic encephalopathy runs a fluctuating course: results from a three-year prospective cohort follow-up study.

1 reference

12 December 2020

Development and evaluation of the quality of life instrument in chronic liver disease patients with minimal hepatic encephalopathy

1 reference

12 December 2020

Critical flicker frequency: diagnostic tool for minimal hepatic encephalopathy

1 reference

12 December 2020

Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy

1 reference

12 December 2020

Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy

1 reference

12 December 2020

[Reduction of hospital stay with the use of L-ornithine L-aspartate (LOLA) in patients with hepatic encephalopathy]

1 reference

12 December 2020

Value of the critical flicker frequency in patients with minimal hepatic encephalopathy

1 reference

12 December 2020

Critical flicker frequency for diagnosis and assessment of recovery from minimal hepatic encephalopathy in patients with cirrhosis.

1 reference

12 December 2020

IL-6 and IL-18 in blood may discriminate cirrhotic patients with and without minimal hepatic encephalopathy

1 reference

12 December 2020

Cognitive impairment in people diagnosed with end-stage liver disease evaluated for liver transplantation

1 reference

12 December 2020

10.1007/S11894-010-0150-Z

Identifiers

DOI

1 reference

23 August 2017

1 reference